List view / Grid view
20 April 2017 | By Niamh Marriott, Junior Editor
Novartis has entered into a clinical trial agreement with Allergan to conduct a Phase IIb study, involving the combination of a Novartis’ FXR agonist...
19 April 2017 | By Niamh Marriott, Junior Editor
GeNeuro have started a Phase 2a clinical study in Australia with GNbAC1 in patients with Type 1 diabetes. GNbAC1 is a monoclonal antibody designed to...
19 April 2017 | By Munters
Munters, global leaders in energy efficient air treatment, is delighted to be exhibiting on Stand 106 at Making Pharmaceuticals...
19 April 2017 | By Niamh Marriott, Junior Editor
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Novartis’ CTL019, an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of adult patients with relapsed and refractory (r/r) diffuse large B-cell lymphoma (DLBCL), who have failed two or more prior therapies. This is…
19 April 2017 | By Niamh Marriott, Junior Editor
The US Food and Drug Administration (FDA) has granted Enzyvant’s RVT-802, an investigational tissue-based therapy for the treatment of complete DiGeorge Syndrome (cDGS), breakthrough therapy designation as well as regenerative medicine advanced therapy (RMAT) designation. Both designations confer special access to the Office of Tissues and Advanced Therapies for development…
19 April 2017 | By Precision Polymer Engineering
Precision Polymer Engineering will be at Stand 303 at Making Pharmaceuticals (25-26 April, Coventry, UK), offering the benefits of our experience in pharmaceutical sealing to solve problems for critical process applications...
18 April 2017 | By Niamh Marriott, Junior Editor
Rigel Pharmaceuticals has submitted a new drug application to the US FDA for fostamatinib in patients with immune thrombocytopenia...
18 April 2017 | By Niamh Marriott, Junior Editor
Amarantus Bioscience has formed a wholly-owned subsidiary named Elto Pharma for the purpose of creating investment vehicles focused exclusively on the further development of Eltoprazine, Amarantus' mid-stage central nervous system (CNS) symptomatic treatment for Adult Attention Deficit and Hyperactivity Disorder (Adult ADHD), Alzheimer's Aggression and Parkinson's disease Levodopa-induced Dyskinesia (PD-LID).
13 April 2017 | By Niamh Marriott, Junior Editor
A new childhood absence epilepsy study has identified genes that show individual reactions and could be used as a precision medicine approach...
12 April 2017 | By Steve Bremer, Managing Editor
The Biophorum Operations Group BPOG has published a best-practices guide for evaluating leachables risk from single-use systems (SUS)...
12 April 2017 | By Niamh Marriott, Junior Editor
The US Food and Drug Administration (FDA) has approved Ingrezza (valbenazine) capsules to treat adults with tardive dyskinesia. This is the first drug approved by the FDA for this condition. Tardive dyskinesia is a neurological disorder characterised by repetitive involuntary movements, usually of the jaw, lips and tongue, such as…
Lonza is hosting a free 60-minute webinar on 25 April 2017 on how to create a compelling business case for the implementation of a paperless QC testing solution.
10 April 2017 | By Niamh Marriott, Junior Editor
Therapix Biosciences has signed a sublicense agreement for Yissum Research Development Company of the Hebrew University nasal drug delivery technology...
7 April 2017 | By Niamh Marriott, Junior Editor
Jazz Pharmaceuticals completed a rolling submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for the approval of Vyxeos...
6 April 2017 | By Niamh Marriott, Junior Editor
BTG has received Class III CE Mark certification for DC Bead LUMI, the first commercially available radiopaque drug-eluting bead...
